medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2011; 10 (1)


Epidemiological assessment of liver disease in northeastern Brazil by means of a standardized liver biopsy protocol

Lembrança L, Medina J, Portugal M, Almeida D, Solla J, Gadelha R, de Freitas LAR, Paraná R

Idioma: Ingles.
Referencias bibliográficas: 30
Paginas: 43-49
Archivo PDF: 61.59 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bravo AA, Sheth SG, Chopra S. Liver Biopsy. New England J Medicine 2001; 344: 495-500.

  2. Sporea I, Popescu A, Sirli R. Why, who and how should perform liver biopsy in chronic liver diseases. WJG 2008; 14: 3396-402.

  3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C: The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Lancet 1997; 349: 825-32.

  4. Codes L, de Freitas LA, Santos-Jesus R, Vivitski L, Silva LK, Trepo C, Reis MG, et al. Comparative Study of Hepatitis C Virus Genotypes 1 and 3 in Salvador, Bahia. Braz J Infect Dis 2003; 7: 409-17.

  5. Kleiner DE. The liver biopsy in chronic hepatitis C: a view from the other side of the microscope. Semin Liv Dis 2005; 25: 52-64.

  6. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French survey of 6,664 patients. Hepatol 1997; 26: 485-90.

  7. Rockey DC, SH Caldwell, ZD Goodman, RC Nelson, AD Smith. Liver Biopsy. Hepatol 2009; 49: 1017-44.

  8. Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H. Hepatology: a clinical textbook. Duesseldorf: Flying Publisher; 2009.

  9. Malik AH, Kumar KS, Malet PF, Jain R, Prasad P, Ostapowicz G. Correlation of percutaneous liver biopsy fragmentation with the degree of fibrosis. Aliment Pharmacol Therap 2004; 19: 545-9.

  10. D’Souza RF, Feakins R, Mears L, Sabin CA, Foster GR. Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and ?brosis progression in patients with chronic hepatitis C. Aliment Pharmacol Therap 2005; 21: 519-24.

  11. Sikorska K, Stalke P, Izycka-Swieszewska E, Romanowski T, Bielawski KP. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C. Med Sci Mon 2010; 16: 137-43.

  12. Paraná R, Lyra L, Trepo C. Intravenous vitamin complexes used in sporting activities and transmission of HCV in Brazil. Am J Gastroenterol 1999; 94: 857-8.

  13. Focaccia R, Baraldo DC, Ferraz ML, Martinelli AL, Carrilho FJ, Gonçales FL Jr, Pedroso ML, et al. Demographic and Anthropometrical Analysis and Genotype Distribution of Chronic Hepatitis C Patients Treated in Public and Private Reference Centers in Brazil. Braz J Infect Dis 2004; 8: 348-55.

  14. Mota AP, Coronado MAB, Morales JG, Vázquez de Castro RR, Muñoz CP, Bach JLV, Aparicio CV. Hepatitis crónica por virus C. Datos epidemiológicos y de eficacia terapéutica en 255 casos. Ann Med Int 2006; 23: 257-9.

  15. Soza A, Arrese M, González R, Alvarez M, Pérez RM, Cortés P, Patillo A, et al. Clinical and epidemiological features of 147 Chilean patients with chronic hepatitis C. Ann Hepatol 2004; 3: 146-51.

  16. Bruguera M, Forns X. Hepatitis C em España. Medicina Clínica 2006; 127:113-117

  17. Conte VP. Hepatite cronica por vírus C – parte 1: Consideraçoes Gerais. Arqu Gastroenterol 2000; 37: 187-94.

  18. Hoofnagle JH. Course and outcome of hepatitis C. Hepatol 2002; 36 (Suppl. 1): S21-S29.

  19. Marcellin P, Asselah T, Boyer N. Fibrosis and Disease Progression in Hepatitis C. Hepatol 2002; 36 (Suppl. 1): S47-S56.

  20. Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatol 1999; 29: 1596-601.

  21. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver ?brosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.

  22. Kim WR, Poterucha JJ, Benson JT, Therneau TM. The Impact of Competing Risks on the Observed Rate of Chronic Hepatitis C Progression. Gastroenterol 2004; 127: 749-55.

  23. de Lédinghen V, Barreiro P, Foucher J, Labarga P, Castéra L, Vispo ME, Bernard PH, et al. Liver ?brosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Vir Hepat 2008; 15: 427-33.

  24. Guyader D, Thirouard AS, Erdtmann L, Rakba N, Jacquelinet S, Danielou H, Perrin M, et al. Liver iron is a surrogate marker of severe ?brosis in chronic hepatitis C. J Hepatol 2007; 46: 587-95.

  25. Martinelli ALC, Ramalho L, Zucoloto S. Hepatic stellate cells in hepatitis C patients: relationship with liver iron deposits and severity of liver disease. J Gastroenterol Hepatol 2004; 19: 91-8.

  26. Silva IS, Perez RM, Oliveira PV, Cantagalo MI, Dantas E, Sisti C, Figueiredo-Mendes C, et al. Iron overload in patients with chronic hepatitis C virus infection: Clinical and histological study. J Gastroenterol Hepatol 2005; 20: 243-8.

  27. Fernandez-Rodriguez CM, Gutiérrez ML, Serrano PL, Lledó JL, Santander C, Fernández TP, Tomás E, et al. Factors Influencing the Rate of Fibrosis Progression in Chronic Hepatitis C. Digest Dis Sci 2004; 49: 1971-6.

  28. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Act Haematol 2009; 122: 78-86.

  29. Tsochatzis E, Papatheodoridis GV, Koliaraki V, Hadziyannis E, Kafiri G, Manesis EK, Mamalaki A, et al. Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C. J Vir Hepat 2009; 16.

  30. Farrel RJ, Smiddy PF, Pilkington RM. Guided versus blind biopsy for chronic hepatitis C: Clinical benefits and costs. J Hepatol 1999; 30: 580-7.




2020     |     www.medigraphic.com